-
2 months ago | 
radcliffecardiology.com | Pablo Vazquez |Marat Fudim |Barry A. Borlaug |Alexander Sullivan
THT Conference 2025 - Findings show catheter ablation of the right greater splanchnic nerve (GSN) in patients with heart failure with preserved ejection fraction (HFpEF) reduced estimated stressed blood volume in patients whether the ablation caused clinical benefits or not. This outcome indicates a confirmation of technical success that correlates with prior single-arm study findings.
-
Nov 17, 2024 | 
hcplive.com | Barry A. Borlaug |Connor Iapoce
Tirzepatide lowered circulatory pressure-volume overload and reduced end-organ damage in the kidney and heart in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to data from the SUMMIT trial.
-
Oct 2, 2024 | 
jamanetwork.com | Marat Fudim |Barry A. Borlaug |Scripps Clinic
Key PointsQuestion
What is the feasibility, safety, and efficacy of endovascular right-sided splanchnic nerve ablation for volume management (SAVM)? Finding
In this phase 2, double-blind, randomized clinical trial including 90 patients, there were no differences in adverse events between groups. The primary efficacy end point did not differ between SAVM and sham.
-
Aug 5, 2024 | 
ahajournals.org | Barry A. Borlaug
Systemic arterial compliance and venous capacitance are typically impaired in patients with heart failure with preserved ejection fraction (HFpEF), contributing to hemodynamic congestion with stress. Sodium-glucose cotransporter-2 inhibitors reduce hemodynamic congestion and improve clinical outcomes in patients with HFpEF, but the mechanisms remain unclear.
-
Aug 2, 2024 | 
jacc.org | Subodh Verma |Mark C. Petrie |Barry A. Borlaug |Javed Butler
References1. "Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets". Cardiovasc Res . 2023;118:3434-3450. 2. "Inflammatory mechanisms in heart failure with preserved ejection fraction". Physiology (Bethesda) . 2023;38:0. 3. "Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions". Cardiovasc Res . 2023;118:3536-3555. 4.
-
Jun 1, 2024 | 
jacc.org | Yogesh N.V. Reddy |Peter A. Noseworthy |Barry A. Borlaug |Nancy M. Albert
References1. "Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation". J Am Coll Cardiol . 2020;76:1051-1064. 2. "Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction". Circulation . 2022;146:339-357. 3. "Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction". Circulation . 2016;133:484-492. 4.
-
Apr 6, 2024 | 
nejm.org | Mikhail Kosiborod |Mark C. Petrie |Barry A. Borlaug |Javed Butler
AbstractObesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes.
-
Apr 2, 2024 | 
jacc.org | Mark C. Petrie |Barry A. Borlaug |Javed Butler |Melanie J. Davies
Introduction In the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) program, the glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide, at a weight-management dose of 2.4 mg once weekly, reduced heart failure (HF)–related symptoms, physical limitations, and body weight in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).1,2 Semaglutide also improved exercise function and lowered levels of systemic inflammation with a...
-
Apr 1, 2024 | 
jacc.org | Barry A. Borlaug |Mark Strong
IntroductionMorbidity and mortality are increased in heart failure with preserved ejection fraction (HFpEF) patients because of elevated pulmonary capillary wedge pressures (PCWP). It is well-established that pericardial constraint increases external pressure on the heart and amplifies the increase in PCWP.1 In patients with HFpEF, a substantial component of pressure elevation in the ventricle is related to external contact pressure exerted by the intact pericardium.
-
Feb 2, 2024 | 
onlinelibrary.wiley.com | Mauro Riccardi |Surgical Specialties |Barry A. Borlaug |Riccardo M. Inciardi
Corresponding Author Riccardo M. Inciardi Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy Corresponding author. Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy.
